Omnicell (OMCL)
(Delayed Data from NSDQ)
$42.39 USD
+0.88 (2.12%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $42.36 -0.03 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.39 USD
+0.88 (2.12%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $42.36 -0.03 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth C Momentum B VGM
Zacks News
Omnicell (OMCL) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Omnicell (OMCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for October 4th
by Zacks Equity Research
OMCL and SFBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 4, 2024.
New Strong Buy Stocks for October 4th
by Zacks Equity Research
KUBTY, OMCL, PDFS, RYAAY and HTH have been added to the Zacks Rank #1 (Strong Buy) List on October 4, 2024.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Should You Continue to Retain OMCL Stock in Your Portfolio Now?
by Zacks Equity Research
Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Earnings Estimates Moving Higher for Omnicell (OMCL): Time to Buy?
by Zacks Equity Research
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Omnicell (OMCL) Introduces Central Med Automation Service
by Zacks Equity Research
Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.
Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 218.75% and 9.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell (OMCL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Omnicell (OMCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell (OMCL) Banks on Product Launches, Global Growth
by Zacks Equity Research
Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.
Here's Why Omnicell (OMCL) Should be in Your Portfolio Now
by Zacks Equity Research
A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).
Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?
by Zacks Equity Research
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell (OMCL) Gains From New Offerings Amid Cost Woes
by Zacks Equity Research
With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.
Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y
by Zacks Equity Research
Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.
Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 137.50% and 4.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GE HealthCare Technologies (GEHC) Meets Q1 Earnings Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of 0% and 3.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.
Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.
Omnicell (OMCL) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 94.12% and 1.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.
Omnicell (OMCL) Gains From Innovation Amid Cost Pressure
by Zacks Equity Research
Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.
Inspire (INSP) Up 16.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.